Welcome to our dedicated page for Eyenovia SEC filings (Ticker: EYEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eyenovia Inc. filings document the company’s transition to Hyperion DeFi, Inc., including the corporate name change, Nasdaq trading symbol change to HYPD, and common stock registration details. Recent 8-K disclosures cover Regulation FD updates, other events, executive and workforce-related governance matters, and material agreements tied to the company’s public-company status.
The filing record also documents a private placement, registration rights, capital-structure disclosures, and the stated use of proceeds for a HYPE reserve and staking program. Related disclosures address the company’s Hyperliquid validator activity, its cryptocurrency treasury strategy, and continuing references to the Gen-2 Optejet User Filled Device within the legacy ophthalmic technology business.
Hyperion DeFi, Inc. will hold its 2025 virtual Annual Meeting on 18 Aug 2025 at 12:00 PM EDT. Stockholders of record as of 18 Jul 2025 will vote on nine items.
- Proposal 1–3: elect five directors, ratify new auditor CBIZ CPAs P.C., and cast a say-on-pay advisory vote.
- Proposal 4: double authorized common stock to 600 million and preferred stock to 60 million. As of 8 Jul 2025 only 244.1 million common and 0.56 million preferred shares remain unissued; the board cites financing flexibility as the main reason.
- Proposal 5: amend the charter to allow stockholders to act by written consent.
- Proposal 6: add 5.3 million shares to the 2018 Omnibus Stock Incentive Plan, raising its pool to 5.73 million shares; just 27,186 shares remain currently.
- Proposal 7: approve issuance of up to 394,236 shares upon warrant exercise under Nasdaq Rule 5635(d).
- Proposal 8: authorize adjournment to solicit more votes if Proposals 4, 5, or 7 lack support.
The proxy discloses a recent auditor transition—Marcum LLP resigned on 2 May 2025 after its attest practice was acquired by CBIZ. Marcum’s 2023–24 reports contained a going-concern paragraph and identified two material weaknesses, which management is addressing.
The charter amendments give the board wide latitude to issue a large number of new shares, potentially introducing dilution risk but also enabling capital raises, M&A and employee incentives. Governance rights improve slightly through the proposed written-consent provision and annual director elections.
Eyenovia, Inc. (Nasdaq: EYEN) has filed a Prospectus Supplement under Form 424B5 to update its existing at-the-market (ATM) equity program with Chardan Capital Markets. The filing registers the offer and sale of up to $14,942,887 in additional common stock, a figure calculated to comply with General Instruction I.B.6 of Form S-3.
• As of 27 June 2025, the company’s non-affiliate public float was approximately $52.8 million, based on 4,853,092 shares at $10.88 per share.
• I.B.6 limits primary offerings to one-third of that float—about $17.6 million—within any 12-month period when the float is under $75 million.
• Eyenovia has already sold $2.66 million of securities during the preceding 12 months, leaving capacity for the newly registered $14.94 million.
The filing does not alter the total $50 million ceiling of the December 30, 2024 amended Sales Agreement, but it refreshes the amount currently eligible for issuance. Shares will be sold from time to time through Chardan acting as sales agent, at market prices on Nasdaq Capital Market under the symbol EYEN.
The supplement reiterates that investment in EYEN entails a high degree of risk and directs investors to previously filed risk factors in the company’s 10-K and 8-K dated 27 June 2025.